|
RTW Biotech Opportunities Ltd on Friday noted positive trial data from investee Artios Pharma, for the ongoing study of its lead candidate ART0380. RTW Biotech is a Guernsey, England-based investment fund which invests in companies that develop next-generation therapies and technologies that can improve patients’ lives. Artios is a private UK-based pharmaceutical company aiming to develop new classes of medicines that exploit DNA damage response pathways to improve outcomes for patients with hard-to-treat cancers. The firm represents 5.3% of RTW Biotech’s net asset value. ART0380 in combination with low-dose irinotecan was shown in the Artios presentation at the American Association for Cancer Research annual meeting to demonstrate a 50% response rate in patients with Ataxia-Telangiectasia Mutated-negative1 solid tumors at the recommended Phase 2 dose. ‘We are thrilled to see the promising results from the Stella Phase 1/2a study of ART0380. The innovative approach of combining ART0380 with low-dose irinotecan to amplify replication stress is groundbreaking and validates Artios’ unique strategy in targeting DNA damage response mechanisms,’ says Rod Wong, chief investment officer at RTW Investments. ‘These unprecedented results not only highlight the potential of ART0380 to significantly improve patient outcomes but also reinforce our confidence in Artios’ leadership in the field of targeted oncology. We were an early investor in Artios and materially increased our position through the Arix transaction. We look forward to the continued development and expansion of this promising therapy.’ Shares in RTW Biotech were up 2.0% at $1.23 in London on Friday afternoon. The stock remains down 6.5% over the past year, however. Copyright 2025 Alliance News Ltd. All Rights Reserved.
|
